Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Univesity Of Melbourne Grattan Street is active in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This prosecution activity is assigned to 1 distinct examiner, indicating a focused and limited scope of active patent office engagement. The involvement of 1 distinct art unit suggests that the university's current filings are concentrated within a specific technical niche of the biotechnology industry, rather than being spread across multiple review groups.
The busiest examiner for the portfolio is ALAM, DANYAL HASSAN, who is overseeing 1 busiest examiner pending office action. As the total count of pending office actions is 1, this examiner is responsible for the entirety of the university's active prosecution workload. This creates a highly focused interaction where the university's immediate patent outcomes are tied to a single examiner's review. For practitioners, this profile shows a very simple prosecution landscape with no current diversification across different examiners or art units in the Biotechnology & Pharmaceuticals field at this time.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269108 | Coronavirus Vaccine | ALAM, DANYAL HASSAN | 9d |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269108 | Coronavirus Vaccine | ALAM, DANYAL HASSAN | 1672 | §102§103§112 | Non-Final OA | 9d | Pending | Jun 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial